JP2015514423A5 - - Google Patents

Download PDF

Info

Publication number
JP2015514423A5
JP2015514423A5 JP2015507095A JP2015507095A JP2015514423A5 JP 2015514423 A5 JP2015514423 A5 JP 2015514423A5 JP 2015507095 A JP2015507095 A JP 2015507095A JP 2015507095 A JP2015507095 A JP 2015507095A JP 2015514423 A5 JP2015514423 A5 JP 2015514423A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
amino acid
acid sequence
bispecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015507095A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514423A (ja
JP6216772B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/036677 external-priority patent/WO2013158577A1/en
Publication of JP2015514423A publication Critical patent/JP2015514423A/ja
Publication of JP2015514423A5 publication Critical patent/JP2015514423A5/ja
Application granted granted Critical
Publication of JP6216772B2 publication Critical patent/JP6216772B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015507095A 2012-04-20 2013-04-16 抗baff−抗il−17二重特異性抗体 Active JP6216772B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261636302P 2012-04-20 2012-04-20
US61/636,302 2012-04-20
US201361768747P 2013-02-25 2013-02-25
US61/768,747 2013-02-25
PCT/US2013/036677 WO2013158577A1 (en) 2012-04-20 2013-04-16 Anti-baff-anti-il-17 bispecific antibodies

Publications (3)

Publication Number Publication Date
JP2015514423A JP2015514423A (ja) 2015-05-21
JP2015514423A5 true JP2015514423A5 (https=) 2016-06-02
JP6216772B2 JP6216772B2 (ja) 2017-10-18

Family

ID=48539373

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015507095A Active JP6216772B2 (ja) 2012-04-20 2013-04-16 抗baff−抗il−17二重特異性抗体

Country Status (39)

Country Link
US (2) US9359448B2 (https=)
EP (2) EP2838920B1 (https=)
JP (1) JP6216772B2 (https=)
KR (1) KR101673735B1 (https=)
CN (1) CN104220455B (https=)
AP (1) AP2014008002A0 (https=)
AR (1) AR090626A1 (https=)
AU (1) AU2013249546B2 (https=)
BR (1) BR112014025649A2 (https=)
CA (1) CA2869148C (https=)
CL (1) CL2014002616A1 (https=)
CO (1) CO7160039A2 (https=)
CR (1) CR20140466A (https=)
CY (1) CY1118824T1 (https=)
DK (1) DK2838920T3 (https=)
DO (1) DOP2014000234A (https=)
EA (1) EA029185B1 (https=)
EC (1) ECSP14023405A (https=)
ES (2) ES2621917T3 (https=)
GT (1) GT201400217A (https=)
HR (1) HRP20170468T1 (https=)
HU (1) HUE032153T2 (https=)
IL (1) IL234965B (https=)
IN (1) IN2014MN01876A (https=)
LT (1) LT2838920T (https=)
ME (1) ME02596B (https=)
MX (1) MX367460B (https=)
MY (1) MY173282A (https=)
NZ (1) NZ630865A (https=)
PE (1) PE20142147A1 (https=)
PH (1) PH12014502333B1 (https=)
PL (1) PL2838920T3 (https=)
PT (1) PT2838920T (https=)
RS (1) RS55729B1 (https=)
SG (1) SG11201406726PA (https=)
SI (1) SI2838920T1 (https=)
TW (1) TWI585103B (https=)
WO (1) WO2013158577A1 (https=)
ZA (1) ZA201407272B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2571901B1 (en) 2010-05-20 2019-01-02 Ablynx N.V. Biological materials related to her3
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
AR090626A1 (es) * 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
TW201444867A (zh) * 2013-03-08 2014-12-01 Lilly Co Eli 抗tnf-抗il-17雙特異性抗體
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
CA2929846C (en) * 2013-11-19 2020-09-15 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
EA033604B1 (ru) 2014-01-31 2019-11-08 Boehringer Ingelheim Int Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
WO2017015433A2 (en) 2015-07-23 2017-01-26 Boehringer Ingelheim International Gmbh Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
CN105061596B (zh) * 2015-08-05 2019-01-29 江苏诺迈博生物医药科技有限公司 人b淋巴细胞刺激因子的单克隆抗体及其应用
US20200385478A1 (en) * 2018-01-05 2020-12-10 Biograph 55, Inc. Compositions and methods for cancer immunotherapy
CN117529506A (zh) * 2021-06-11 2024-02-06 海南先声药业有限公司 抗人il-17抗体和taci的双功能融合蛋白分子
WO2024140930A1 (en) * 2022-12-28 2024-07-04 Suzhou Transcenta Therapeutics Co., Ltd. Bispecific binding protein comprising anti-baff antibody and use thereof
AU2024239150A1 (en) 2023-03-21 2025-10-02 Biograph 55, Inc. Cd19/cd38 multispecific antibodies
WO2025108551A1 (en) 2023-11-23 2025-05-30 Mabylon Ag Multispecific anti-allergen antibodies and uses thereof
WO2025109206A1 (en) 2023-11-22 2025-05-30 Mabylon Ag Multispecific anti-allergen antibodies and uses thereof
WO2025222167A1 (en) * 2024-04-19 2025-10-23 Zb17 Llc Methods of treatment
WO2025222170A1 (en) * 2024-04-19 2025-10-23 Zb17 Llc Methods of treatment
WO2025222168A1 (en) * 2024-04-19 2025-10-23 Zb17 Llc Methods of treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
AR035119A1 (es) * 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
NZ612578A (en) * 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
EP1963368B3 (en) 2005-12-13 2020-06-10 Eli Lilly And Company Anti-il-17 antibodies
US20110293629A1 (en) * 2010-05-14 2011-12-01 Bastid Jeremy Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
AR090626A1 (es) * 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos

Similar Documents

Publication Publication Date Title
JP2015514423A5 (https=)
HRP20170468T1 (hr) Bispecifična protutijela protiv baff i protiv il-17
HRP20201633T1 (hr) Protutijela koja se vežu na il-23
JP2016526909A5 (https=)
JP2022503959A5 (https=)
HRP20192059T1 (hr) Protutijela protiv tau i njihova upotreba
JP2005120106A5 (https=)
MX2015000683A (es) Metodo para producir moleculas monomericas y multimericas y uso de las mismas.
JP2016185981A5 (https=)
HK1207575A1 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
EA201190326A8 (ru) Полипептиды гормона роста и способы их получения и применения
WO2014202616A3 (en) Rasamsonia gene and use thereof
HRP20191446T1 (hr) Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula
JP2015146822A5 (https=)
HRP20191865T1 (hr) Novi heterodimerni proteini
JP2018535196A5 (https=)
JP2019523221A5 (https=)
MX366647B (es) Cambio de temperatura para una expresión con mayor rendimiento de polipéptidos en levaduras y otras células transformadas.
HRP20180155T1 (hr) Novo protutijelo protiv ljudskog ngf
JP2012107050A5 (https=)
FI2956471T3 (fi) Il-1-beetan estäjän koostumus ja sen käyttö
FI3378535T3 (fi) Alfa-synukleiinin tunnistavia humanisoituja vasta-aineita
BR112015018203A2 (pt) Anti-corpos biespecíficos anti-tnf-anti-il-17
JP2014511680A5 (https=)
RU2015129656A (ru) Гуманизированное моноклональное антитело, специфичное к синдекану-1